Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer's Chantix Warning May Remain As FDA Raises Trial Concerns

Executive Summary

FDA will present concerns on data collection and study conduct during advisory committee meeting on removing smoking cessation drug's boxed warning.

You may also be interested in...

Chantix's Boxed Warning: Will A Positive Vote Justify A Negative Outcome?

FDA could use advisory committee members' comments to maintain the smoking cessation drug's boxed warning, even though they voted to remove it.

Was FDA Nit-Picking In Criticism Of Pfizer's EAGLES Trial?

When industry rep questioned whether problems with smoking cession drug trial were overestimated, FDA's rebuke was swift.

Removing Pfizer's Chantix Boxed Warning A One-Off, Committee Says

Advisory committee says data supports dialing back safety label for the smoking cessation product, but shouldn’t be precedent setting.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts